Certainly, the apparent advantage of tirzepatide, a dual incretin agonist, over GLP-1RA will spark renewed interest in the therapeutic potential of GIP in type 2 diabetes, obesity and related co-morbidities. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.